This site uses cookies to measure how you use the website so it can be updated and improved based on your needs and also uses cookies to help remember the notifications you’ve seen, like this one, so that we don’t show them to you again. If you could also tell us a little bit about yourself, this information will help us understand how we can support you better and make this site even easier for you to use and navigate.

This database contains 59 studies, archived under the term: "Spain"

Click here to filter this large number of results.

Human Albumin Grifols 5% in plasmapheresis: a new therapy involving beta-amyloid mobilisation in Alzheimer’s disease
Introduction and Aims: Results from a pilot study and its 2-year extension (IG0502) performed on patients with mild or moderate Alzheimer’s disease revealed a tendency towards clinical stabilization after a plasmapheresis program with plasma exchange with therapeutic albumin Human Albumin Grifols 5%. Plasma levels of Alphabeta(40) and Alphabeta(42) presented a saw-tooth pattern associated to plasma […]

Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer’s disease in Spain (MEMORY study)
Aim: Memantine is the most recently introduced therapy for the treatment of moderately severe to severe Alzheimer’s disease. The aim of this study was to evaluate safety and effectiveness of memantine under normal clinical practice in patients with moderately severe to severe Alzheimer’s disease. Additionally, we assessed the usual prescription guidelines for memantine.; Patients and […]

Orally disintegrating donepezil: are the main caregivers of patients with Alzheimer’s disease more satisfied with this formulation of donepezil than with the traditional one?
Aim: To know whether caregivers of Alzheimer’s disease (AD) patients on donepezil treatment are more satisfied with the orally disintegrating tablet (ODT) formulation than with the film-coated tablets.; Patients and Methods: Multicenter, cross-sectional study of patients with probably AD by DSM-IV or NINCDS-ADRDA criteria, on monotherapy with donepezil, ODT or film-coated tablets. Satisfaction with treatment […]

Effectiveness of a psychoeducational intervention program in the reduction of caregiver burden in Alzheimer’s disease patients’ caregivers
Objectives: Caregivers of patients with Alzheimer’s disease (AD) experience physical and psychological stress due to the caring experience. This study evaluated the benefits of a Psychoeducational Intervention Program (PIP) on caregiver burden in southern Europe.; Methods: A multicentre, prospective, randomised study was conducted. One hundred and fifteen caregivers of patients with clinical diagnosis of AD […]

Vitamin E paradox in Alzheimer’s disease: it does not prevent loss of cognition and may even be detrimental
There is controversy as to whether vitamin E is beneficial in Alzheimer’s disease (AD). In this study, we tested if vitamin E prevents oxidative stress and loss of cognition in AD. Fifty-seven AD patients were recruited and divided in two groups: placebo or treated with 800 IU of vitamin E per day for six months. […]

Reduced TNF-α and increased IGF-I levels in the serum of Alzheimer’s disease patients treated with the neurotrophic agent cerebrolysin
According to current scientific knowledge, excess tumour necrosis factor-α (TNF-α) and low insulin-like growth factor-I (IGF-I) are pathogenic-risk factors that constitute therapeutic targets for Alzheimer’s disease (AD). Changes in serum TNF-α, total and dissociable IGF-I levels were determined by ELISA in 207 AD patients completing a 24-wk, double-blind, placebo-controlled trial to evaluate the effects of […]

Antihypertensive agents and risk of Parkinson’s disease, essential tremor and dementia: a population-based prospective study (NEDICES)
Background: Recent interest in antihypertensive agents, especially calcium channel blockers, has been sparked by the notion that these medications may be neuroprotective. A modest literature, with mixed results, has examined whether these medications might lower the odds or risk of Parkinson’s disease (PD) or dementia. There are no data for essential tremor (ET).; Objective: To […]

Safety and efficacy of galantamine (Reminyl) in severe Alzheimer’s disease (the SERAD study): a randomised, placebo-controlled, double-blind trial
Background: The efficacy of galantamine has been shown in patients with mild, moderate, and advanced moderate Alzheimer’s disease (AD). Here we report its efficacy in patients with severe AD.; Methods: Between December, 2003, and March, 2007, patients aged 84 (SD 6) years with severe AD (mini-mental state examination [MMSE] score 5-12 points), in a nursing […]

Influence of memory strategies on memory test performance: a study in healthy and pathological aging
The ability to generate memory strategies is a key factor in the performance of episodic memory tasks. Whether the ability to generate memory strategies exerts an influence in the performance of memory tests in the elderly population is still a matter of debate. Here we present results from an experimental memory task (Test of Memory […]

The GERAS study: A prospective observational study of costs and resource use in community dwellers with Alzheimer’s disease in three European countries—Study design and baseline findings
To address socioeconomic challenges associated with its increasing prevalence, data are needed on country-level resource use and costs associated with Alzheimer’s disease (AD). GERAS is an 18-month observational study being conducted in France, Germany, and the UK (with an 18-month extension in France and Germany), aimed at determining resource use and total costs associated with […]

Try searching our database by another keyword...

To make a new query of the database, please enter your search terms below:

�

Contact Us